[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA55611A - Association de chir99021 et d'acide valproïque pour traiter une perte auditive - Google Patents

Association de chir99021 et d'acide valproïque pour traiter une perte auditive

Info

Publication number
MA55611A
MA55611A MA055611A MA55611A MA55611A MA 55611 A MA55611 A MA 55611A MA 055611 A MA055611 A MA 055611A MA 55611 A MA55611 A MA 55611A MA 55611 A MA55611 A MA 55611A
Authority
MA
Morocco
Prior art keywords
chir99021
combination
hearing loss
valproic acid
treat hearing
Prior art date
Application number
MA055611A
Other languages
English (en)
Inventor
Moraye Bear
Jenna Herby
Ashley Hinton
Carl Lebel
Christopher Loose
Will Mclean
Original Assignee
Frequency Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frequency Therapeutics Inc filed Critical Frequency Therapeutics Inc
Publication of MA55611A publication Critical patent/MA55611A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA055611A 2019-04-08 2020-04-08 Association de chir99021 et d'acide valproïque pour traiter une perte auditive MA55611A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831167P 2019-04-08 2019-04-08
US201962831169P 2019-04-08 2019-04-08
US201962831170P 2019-04-08 2019-04-08

Publications (1)

Publication Number Publication Date
MA55611A true MA55611A (fr) 2022-02-16

Family

ID=70476486

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055611A MA55611A (fr) 2019-04-08 2020-04-08 Association de chir99021 et d'acide valproïque pour traiter une perte auditive

Country Status (14)

Country Link
US (1) US20220175776A1 (fr)
EP (1) EP3952854A1 (fr)
JP (1) JP2022527391A (fr)
KR (1) KR20220007050A (fr)
CN (1) CN114340611A (fr)
AU (1) AU2020271067A1 (fr)
BR (1) BR112021020141A2 (fr)
CA (1) CA3136424A1 (fr)
IL (1) IL287094A (fr)
MA (1) MA55611A (fr)
MX (1) MX2021012258A (fr)
SG (1) SG11202111191YA (fr)
TW (1) TW202103692A (fr)
WO (1) WO2020210388A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4251127A1 (fr) * 2020-11-26 2023-10-04 Alain Moussy Composition pharmaceutique pour le traitement de troubles de l'oreille interne par administration locale dans la zone tympanique

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
CA2568028A1 (fr) 2004-05-24 2005-12-08 Auris Medical, Llc. Combine aspirateur otique et distributeur de medicament
CA2714370C (fr) 2008-02-07 2017-05-02 Massachusetts Eye & Ear Infirmary Composes stimulant l'expression du gene atoh-1
CA2823719A1 (fr) 2011-01-24 2012-08-02 The Board Of Trustees Of The Leland Stanford Junior University Procedes de generation de cellules de l'oreille interne in vitro
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
EP2606884A1 (fr) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement des cancers
JP6138928B2 (ja) 2012-06-01 2017-05-31 ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー） 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
WO2014047391A1 (fr) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Promédicaments de composés 1,4-benzodiazépinones
WO2014047370A1 (fr) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Composés fluoroalkyl benzodiazépinones
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
CN105308030A (zh) 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
WO2014047392A1 (fr) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Composés fluoroalkyl-1,4-benzodiazépinones
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
WO2016022776A2 (fr) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Augmentation de la durée de vie d'atoh1 pour diriger la différenciation des cellules ciliées neurosensorielles
SG11201701844YA (en) 2014-10-08 2017-04-27 Agency Science Tech & Res Methods of differentiating stem cells into liver cell lineages
TWI625332B (zh) 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物
WO2017151907A1 (fr) 2016-03-02 2017-09-08 Frequency Therapeutics, Inc. Méthodes de régulation de la prolifération de cellules souches / de la génération de cellules auditives de l'oreille interne à l'aide d'inhibiteurs de la gsk-3-alpha
CN109311878B (zh) 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
EP3481829B1 (fr) 2016-07-08 2021-04-07 H. Hoffnabb-La Roche Ag Dérivés fusionnés de pyrimidine
JP6980751B2 (ja) 2016-07-14 2021-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
JP6956175B2 (ja) 2016-10-04 2021-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式ヘテロアリール誘導体
TWI757360B (zh) 2016-11-08 2022-03-11 瑞士商赫孚孟拉羅股份公司 苯氧基三唑
WO2018111926A2 (fr) 2016-12-16 2018-06-21 Inception 3, Inc. Méthodes de traitement de la synaptopathie cochléaire
WO2018118782A2 (fr) 2016-12-20 2018-06-28 Oligomerix, Inc. Nouveaux analogues de benzofuranes, de benzothiophènes et d'indoles qui inhibent la formation d'oligomères tau et leur procédé d'utilisation
ES2953474T3 (es) 2016-12-20 2023-11-13 Oligomerix Inc Nuevas quinazolinonas que inhiben la formación de oligómeros de tau y su modo de uso
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
KR20190104359A (ko) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법
WO2018172997A1 (fr) 2017-03-24 2018-09-27 Novartis Ag Composés d'isoxazole carboxamides et leurs utilisations
US20200080055A1 (en) * 2018-08-17 2020-03-12 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating pi3k
AU2019321641A1 (en) * 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
CN113164381A (zh) * 2018-10-02 2021-07-23 频率医疗公司 有关耳用治疗剂的药物组合物及方法

Also Published As

Publication number Publication date
BR112021020141A2 (pt) 2021-12-21
IL287094A (en) 2021-12-01
AU2020271067A1 (en) 2021-11-25
JP2022527391A (ja) 2022-06-01
EP3952854A1 (fr) 2022-02-16
SG11202111191YA (en) 2021-11-29
CN114340611A (zh) 2022-04-12
US20220175776A1 (en) 2022-06-09
KR20220007050A (ko) 2022-01-18
WO2020210388A1 (fr) 2020-10-15
TW202103692A (zh) 2021-02-01
CA3136424A1 (fr) 2020-10-15
MX2021012258A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA41010A (fr) Compositions comprenant des souches bactériennes
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
AU2017260532A1 (en) Methods and devices for preparation of ultrasound contrast agents
MA55611A (fr) Association de chir99021 et d'acide valproïque pour traiter une perte auditive
MA42614A (fr) Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
IL288269A (en) Preparations containing cetyl fatty acids and their use in the treatment of arthritis and inflammatory conditions in the joints
WO2017077528A3 (fr) Procédés et compositions pharmaceutiques pour le traitement d'inflammations pulmonaires
MA54873A (fr) Compositions et méthodes pour le traitement de troubles neurocognitifs
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
MA41142A (fr) Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
EP4017880A4 (fr) Utilisation de brazikumab pour traiter la maladie de crohn
MA50575A (fr) Préparation d'acide phosphorique
MA45609A (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite
MA53976A (fr) Anticorps de chimiokine pan-elr + cxc pour le traitement de l'hidradénite suppurativa
MA52634A (fr) Acide nucléique pour traitement de d'allergie aux acariens
MA51831A (fr) Composition pour la prévention et le traitement de troubles de la pousse des cheveux
MA52584A (fr) Acide nucléique pour traitement de d'allergie aux crustacés